China Pharma Holdings EBITDA Margin 2012-2026 | CPHI
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for China Pharma Holdings (CPHI) over the last 10 years. The current EBITDA margin for China Pharma Holdings as of March 31, 2026 is .
| China Pharma Holdings EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2026-03-31 | $0.00B | $0.00B | -25.00% |
| 2025-12-31 | $0.00B | $0.00B | -25.00% |
| 2025-09-30 | $0.00B | $0.00B | -25.00% |
| 2025-06-30 | $0.00B | $0.00B | -25.00% |
| 2025-03-31 | $0.00B | $0.00B | -50.00% |
| 2024-12-31 | $0.00B | $0.00B | -50.00% |
| 2024-09-30 | $0.01B | $0.00B | -20.00% |
| 2024-06-30 | $0.01B | $0.00B | -16.67% |
| 2024-03-31 | $0.01B | 0 | 0.00% |
| 2023-12-31 | $0.01B | 0 | 0.00% |
| 2023-09-30 | $0.01B | $0.00B | -12.50% |
| 2023-06-30 | $0.01B | $0.00B | -12.50% |
| 2023-03-31 | $0.01B | $0.00B | -11.11% |
| 2022-12-31 | $0.01B | $0.00B | -11.11% |
| 2022-09-30 | $0.01B | 0 | 0.00% |
| 2022-06-30 | $0.01B | 0 | 0.00% |
| 2022-03-31 | $0.01B | 0 | 0.00% |
| 2021-12-31 | $0.01B | 0 | 0.00% |
| 2021-09-30 | $0.01B | 0 | 0.00% |
| 2021-06-30 | $0.01B | 0 | 0.00% |
| 2021-03-31 | $0.01B | $0.00B | 9.09% |
| 2020-12-31 | $0.01B | $0.00B | 9.09% |
| 2020-09-30 | $0.01B | $-0.02B | -154.55% |
| 2020-06-30 | $0.01B | $-0.02B | -154.55% |
| 2020-03-31 | $0.01B | $-0.02B | -180.00% |
| 2019-12-31 | $0.01B | $-0.02B | -163.64% |
| 2019-09-30 | $0.01B | $-0.01B | -63.64% |
| 2019-06-30 | $0.01B | $-0.01B | -72.73% |
| 2019-03-31 | $0.01B | $-0.01B | -72.73% |
| 2018-12-31 | $0.01B | $-0.01B | -58.33% |
| 2018-09-30 | $0.01B | $-0.01B | -100.00% |
| 2018-06-30 | $0.01B | $-0.01B | -92.86% |
| 2018-03-31 | $0.01B | $-0.01B | -100.00% |
| 2017-12-31 | $0.01B | $-0.02B | -115.38% |
| 2017-09-30 | $0.01B | $-0.01B | -35.71% |
| 2017-06-30 | $0.01B | $-0.01B | -35.71% |
| 2017-03-31 | $0.02B | $-0.01B | -33.33% |
| 2016-12-31 | $0.02B | $-0.01B | -31.25% |
| 2016-09-30 | $0.02B | $-0.02B | -100.00% |
| 2016-06-30 | $0.02B | $-0.01B | -64.71% |
| 2016-03-31 | $0.02B | $-0.01B | -42.11% |
| 2015-12-31 | $0.02B | $-0.01B | -52.38% |
| 2015-09-30 | $0.02B | $-0.02B | -94.74% |
| 2015-06-30 | $0.02B | $-0.03B | -133.33% |
| 2015-03-31 | $0.02B | $-0.04B | -180.95% |
| 2014-12-31 | $0.02B | $-0.04B | -168.18% |
| 2014-09-30 | $0.03B | $-0.02B | -88.89% |
| 2014-06-30 | $0.03B | $-0.02B | -68.97% |
| 2014-03-31 | $0.03B | $-0.02B | -51.61% |
| 2013-12-31 | $0.03B | $-0.02B | -53.13% |
| 2013-09-30 | $0.04B | $-0.01B | -27.78% |
| 2013-06-30 | $0.04B | $-0.01B | -15.00% |
| 2013-03-31 | $0.05B | $0.00B | 2.13% |
| 2012-12-31 | $0.06B | $0.01B | 14.55% |
| 2012-09-30 | $0.07B | $0.01B | 21.54% |
| 2012-06-30 | $0.07B | $0.02B | 24.32% |
| 2012-03-31 | $0.08B | $0.02B | 26.58% |
| 2011-12-31 | $0.08B | $0.02B | 28.40% |
| 2011-09-30 | $0.08B | $0.03B | 31.33% |
| 2011-06-30 | $0.08B | $0.03B | 33.33% |
| 2011-03-31 | $0.08B | $0.03B | 34.62% |
| 2010-12-31 | $0.08B | $0.03B | 34.67% |
| 2010-09-30 | $0.07B | $0.02B | 33.80% |
| 2010-06-30 | $0.07B | $0.03B | 36.76% |
| 2010-03-31 | $0.07B | $0.02B | 36.92% |
| 2009-12-31 | $0.06B | $0.02B | 36.51% |
| 2009-09-30 | $0.06B | $0.02B | 39.66% |
| 2009-06-30 | $0.06B | $0.02B | 36.36% |
| 2009-03-31 | $0.05B | $0.02B | 36.54% |
| 2008-12-31 | $0.05B | $0.02B | 39.22% |
| 2008-09-30 | $0.05B | $0.02B | 40.00% |
| 2008-06-30 | $0.04B | $0.02B | 40.00% |
| 2008-03-31 | $0.04B | $0.02B | 39.47% |
| 2007-12-31 | $0.03B | $0.01B | 36.36% |
| 2007-09-30 | $0.03B | $0.01B | 34.38% |
| 2007-06-30 | $0.03B | $0.01B | 34.48% |
| 2007-03-31 | $0.02B | $0.01B | 37.50% |
| 2006-12-31 | $0.02B | $0.01B | 40.91% |
| 2006-09-30 | $0.02B | $0.01B | 50.00% |
| 2006-06-30 | $0.02B | $0.01B | 50.00% |
| 2006-03-31 | $0.01B | $0.01B | 50.00% |
| 2003-09-30 | $0.00B | 0 | 0.00% |
| 2002-12-31 | $0.00B | 0 | 0.00% |
| 2002-09-30 | $0.00B | 0 | 0.00% |
| 2001-12-31 | $0.00B | 0 | 0.00% |
| 2001-09-30 | $0.00B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |